Method to enhance tissue accumulation of radiolabeled compounds

• US 6,630,123 B1
• Filed: 09/18/2000
• Issued: 10/07/2003
• Est. Priority Date: 11/24/1997
• Status: Expired due to Fees

• Current Assignee: Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Original Assignee: Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Inventors: Woltering, Eugene A., Espenan, Gregory D.
• Primary Examiner(s): JONES, DAMERON LEVEST
• Application Number:
  US09/664,456
• Time in Patent Office: 1,114 Days
• Field of Search: 424/1.11, 424/1.65, 424/1.69, 424/9.1, 424/9.2, 424/9.3, 424/9.4, 424/9.5, 424/9.6, 530/300, 530/311, 530/317, 530/312, 530/324-330, 514/2, 514/5, 514/6, 514/7, 514/8, 514/9, 514/806
• US Class Current: 424/1.69
• CPC Class Codes: A61K 51/08 Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
• CPC Class Codes: A61K 51/083 the peptide being octreotide or a somatostatin-receptor-binding peptide

Abstract

Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that accumulates in the target cell. The efficacy of the administration of the radiolabeled compound can be increased about five times higher than prior bolus injection or short infusion methods. This method enhances the tumor to background ratio by increasing the actual radioligand accumulated inside the target cells. This technique works for any radiolabeled compound whose cellular uptake is limitedly a cellular process of either binding to a cellular receptor or to a transport protein. Once the radiolabeled compound is bound and internalized, the ability of an unlabeled compound to compete with the radioligand is markedly decreased. The primary factor governing residence time after internalization is the physical half-life of the radioisotope, not biologic half-life.

Claims

1. A method for selectively accumulating a receptor-dependent radiolabeled compound inside target cells in a patient, wherein the target cells are selected from the group consisting of tumor cells and angiogenic cells, wherein the target cells express receptors for the compound, comprising:

(a) selecting a radiolabeled compound from a group comprising analogs and derivatives of receptor-dependent peptides wherein the compound is bound to a radioisotope and wherein the compound binds to the same target cell receptor and accumulates in the target cell in a qualitatively similar manner as that of the receptor-dependent peptide, wherein the receptor-dependent peptide is selected from a group consisting of nerve growth factor, fibroblast growth factor, epidermal growth factor, platelet-derived growth factor, vascular endothelial growth factor, cholecystokinin, vasoactive intestinal peptide, gastrin-releasing peptide, leukemia inhibitory factor, somatostatin, oxytocin, bombesin, calcitonin, arginine vasopressin, angiotensin II, atrial natriuretic peptide, insulin, glucagon, prolactin, growth hormone, gonadotropin, thyrotropin-releasing hormone, growth hormone-releasing hormone, gonadotropin-releasing hormone, corticotropin-releasing hormone, interleukins, interferons, transferrin, substance P, neuromedin, neurotensin, neuropeptide Y; and

(b) comprising administering a dose of the radiolabeled compound to the patient by infusion during a period greater than two hours;

wherein the resulting residence time of the radiolabeled compound in the target cells is at least one and one-half (1.5) times the residence time of the radiolabeled compound in the target cells that would result from a bolus administration of the same total dose of the same radiolabeled compound to the patient.

2. The method of claim 1, wherein the rate of infusion is approximately equal to the rate of cellular uptake and translocation to the nucleus of the radiolabeled compound by the tumor cells.

3. The method of claim 1, wherein the period of infusion is between about 4 hours and about 30 days.

4. The method of claim 1, wherein the period of infusion is between about 24 hours and about 5 days.

5. The method of claim 1, wherein said target cells are tumor cells.

6. The method of claim 1, wherein said target cells are angiogenic cells.

7. The method of claim 1, wherein said radioisotope has a half-life between about 1 hour and about 60 days.

8. The method of claim 1, wherein said radioisotope has a half-life between about 2 hours and about 60 days.

9. The method of claim 1, wherein said radioisotope has a half-life between about 12 hours and about 60 days.

10. The method of claim 1, wherein said radioisotope is selected from the group consisting of ⁶⁷Ga, ¹¹¹In, ^99mTc, ⁹⁰Y, ⁸⁶Y, ¹⁶⁹Yb, ¹⁸⁸Re, ¹²⁵I, ¹²³I, ¹²⁴I, ¹²⁹I, ¹³¹I, and ⁷⁷Br.

11. The method of claim 1, further comprising the step of imaging radioactivity in the area of said target cells by scintigraphy.

12. The method of claim 1, further comprising the step of repeating the method of claim 1 until there is at least a 50% decrease in a tumor marker as measured by biochemical and radiographical techniques.

13. The method of claim 1, wherein said radiolabeled compound is ¹¹¹In-pentetreotide.

14. A method for selectively accumulating a receptor-dependent radiolabeled compound inside target cells in a patient, wherein the target cells are tumor cells, wherein the target cells express receptors for the compound, comprising:

(a) selecting a radiolabeled compound from a group comprising analogs and derivatives of receptor-dependent steroids wherein the compound is bound to a radioisotope and wherein the compound binds to the same target cell receptor and accumulates in the target cell in a qualitatively similar manner as that of the receptor-dependent steroid, wherein the-receptor-dependent steroid is selected from a group comprising estrogen, testosterone, progesterone, glucocorticosteroids, and mineralocorticoids; and

(b) comprising administering a dose of the radiolabeled compound to the patient by infusion during a period greater than two hours;

wherein the resulting residence time of the radiolabeled compound in the target cells is at least one and one-half (1.5) times the residence time of the radiolabeled compound in the target cells that would result from a bolus administration of the same total dose of the same radiolabeled compound to the patient.

15. The method of claim 14, wherein said radioisotope has a half-life between about 1 hour and about 60 days.

16. The method of claim 14, wherein said radioisotope has a half-life between about 2 hours and about 60 days.

17. The method of claim 14, wherein said radioisotope has a half-life between about 12 hours and about 60 days.

18. The method of claim 14, wherein said radioisotope is selected from the group consisting of ⁶⁷Ga, ¹¹¹In, ^99mTc, ⁹⁰Y, ⁸⁶Y, ¹⁶⁹Yb, ¹⁸⁸Re, ¹²⁵I, ¹²³I, ¹²⁴I, ¹²⁹I, ¹³¹I, and ⁷⁷Br.

19. The method of claim 14, further comprising the step of imaging radioactivity in the area of said target cells by scintigraphy.

20. The method of claim 14, further comprising the step of repeating the method of claim 14 until there is at least a 50% decrease in a tumor marker as measured by biochemical and radiographical techniques.